ONO Pharmaceutical
Main (gene editing) focus: Next-generation cell therapies
Company stage: Commercial
Diseases: Cancer
Genome editing tool: CRISPR
Funding stage: Public (OTC:OPHLY)
Location: Osaka, Osaka, Japan
Website: https://www.ono-pharma.com/
Pipeline: https://www.ono-pharma.com/ir/library/pipeline.html
Partners: Fate Therapeutics
ONO Pharmaceutical is a global pharmaceutical company headquartered in Japan. The company's engagement in the gene-editing space comes through its collaboration with Fate Therapeutics. The two companies will develop multiple off-the-shelf cell therapies incorporating multiple gene edits.